Drug Profile
Research programme: orexin receptor antagonists - Actelion/GlaxoSmithKline
Latest Information Update: 27 Jun 2017
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals; GlaxoSmithKline
- Developer Actelion Pharmaceuticals; GSK
- Class
- Mechanism of Action Orexin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sleep disorders
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Sleep-disorders in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in Sleep-disorders in United Kingdom